P-Selectin–Targeting Nanoparticles to Boost Immunotherapy in Fibrotic Cancers
Official title: P-Selectin-Targeting Nanoparticles to Potentiate Cancer Immunotherapy
Funded at Sloan-Kettering Inst Can Research · NIH-11455014 · Data updated 2026-11-12
Aims to use special nanoparticles that home in on aging cells in fibrotic tumors to make CAR T cell therapy and immune blockers work better for people with certain lung and liver cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $709,145 |
| NIH project number | 1R01CA305504-01A1 |
| Project ID | NIH-11455014 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with fibrotic lung or liver cancers where fibrotic tumor microenvironments impede immunotherapy.
✕Less likely to help
Patients whose tumors do not exhibit fibrotic or senescent features may not benefit from this targeted approach.
What this research studies
This project uses senescence-targeting nanoparticles to deliver therapy directly to fibrotic tumor environments where traditional immunotherapies struggle. The approach links a senescence-modulating drug with a P-selectin–binding nanoparticle, enabling targeted delivery and in vivo tracking. Researchers will evaluate safety and effectiveness in lung adenocarcinoma and hepatocellular carcinoma models, with the goal of improving responses to immunotherapies. The work builds on prior findings that reducing fibrosis and senescence signals can enhance anti-tumor immune activity.
Why it matters
Potential benefit: If successful, patients with fibrotic tumors could experience better responses to immunotherapy and fewer side effects from treatment.
How similar studies have gone: Preclinical data suggest that targeting senescence and fibrosis can improve immunotherapy in solid tumors, supporting translational potential.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Lowe, Scott W. — Sloan-Kettering Inst Can Research
- Study coordinator: Lowe, Scott W.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.